REZENOPY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rezenopy, and when can generic versions of Rezenopy launch?
Rezenopy is a drug marketed by Summit Biosci and is included in one NDA.
The generic ingredient in REZENOPY is naloxone hydrochloride. There are twelve drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rezenopy
A generic version of REZENOPY was approved as naloxone hydrochloride by HOSPIRA on September 24th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REZENOPY?
- What are the global sales for REZENOPY?
- What is Average Wholesale Price for REZENOPY?
Summary for REZENOPY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 1,704 |
| DailyMed Link: | REZENOPY at DailyMed |
Pharmacology for REZENOPY
| Drug Class | Opioid Antagonist |
| Mechanism of Action | Opioid Antagonists |
US Patents and Regulatory Information for REZENOPY
REZENOPY is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting REZENOPY
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Summit Biosci | REZENOPY | naloxone hydrochloride | SPRAY;NASAL | 215487-001 | Apr 19, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
